| Bioactivity | HDAC8-IN-3 (compound P19) is a potent HDAC8 inhibitor with IC50 value of 9.3 μM and produces thermal stabilization. HDAC8-IN-3 has cytotoxicity and induces apoptosis in leukemic cell lines[1]. |
| Invitro | HDAC8-IN-3 (compound P19) (5-200 μM, 48 hours; HEK293T cells) has cytotoxicity in leukemic cell lines[1].HDAC8-IN-3 (compound P19) (50 μM) inhibits glucose transporter 1 (GLUT1)-mediated glucose transport by down-regulating GLUT1 expression (IC50 = 28.2 μM)[1].HDAC8-IN-3 (compound P19) (79.9 μM; 24 hours) can induce apoptotic death in the CEM cell line[1]. Cell Cytotoxicity Assay[1] Cell Line: |
| Name | HDAC8-IN-3 |
| CAS | 2432825-93-7 |
| Formula | C18H12N4O3S2 |
| Molar Mass | 396.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Upadhyay N, et al. Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation. Bioorg Chem. 2020 Jul;100:103934. |
HDAC8-IN-3
CAS: 2432825-93-7 F: C18H12N4O3S2 W: 396.44
HDAC8-IN-3 (compound P19) is a potent HDAC8 inhibitor with IC50 value of 9.3 μM and produces thermal stabilization. HDA
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.